Revdofilimab clinical trials
Also written ABBV-368.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses revdofilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ABBV-368
- 4
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test revdofilimab.
Studies
Open first, then newest update. How each study uses revdofilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1AbbVieNCT03893955Written as ABBV-368
- A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedPhase 1AbbVieNCT04196283Written as ABBV-368
- A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1AbbVieNCT03071757Written as ABBV-368
- A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedPhase 1AbbVieNCT03818542Written as ABBV-368
Codes
What other systems call revdofilimab · ClinicalTrials.gg INT014552
- UNII (FDA) 2Y83Y2ORD3REVDOFILIMABOne source FDA
- NCI Thesaurus C161864RevdofilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2Y83Y2ORD3 | REVDOFILIMAB | One source FDA |
| NCI Thesaurus | C161864 | Revdofilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.